MarketCap
Facebook
X
Telegram
Organovo Holdings Revenue | ONVO
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Organovo Holdings
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 131 K | 144 K | 109 K | 370 K | 1.5 M | - | 2.2 M | 3.09 M | 4.6 M | 4.23 M | 1.48 M | 571 K | 379 K | 220 K | 1.2 M | - | 603 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.6 M | 109 K | 1.39 M |
Quarterly Revenue Organovo Holdings
| 2027-Q1 | 2026-Q4 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 37 K | - | 26 K | 28 K | 37 K | - | 24 K | 30 K | 39 K | - | 5 K | - | 75 K | - | 131 K | 77 K | 77 K | 1.5 M | - | - | - | - | - | - | - | - | 298 K | 298 K | 1.23 M | 668 K | 779 K | 779 K | 943 K | 1.1 M | 832 K | 946 K | 944 K | 812 K | 699 K | 2.4 M | 1.7 M | 891 K | 293 K | 689 K | 396 K | 306 K | 139 K | 139 K | - | 99 K | 135 K | 264 K | 129 K | - | 349 K | 1.08 M | 728 K | - | - | 232 K | 1.68 K | 1.68 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.4 M | 1.68 K | 497 K |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Syneos Health
SYNH
|
5.39 B | - | - | $ 4.46 B |  USA |
 |
Motus GI Holdings
MOTS
|
319 K | - | -34.28 % | $ 263 K |  Israel |
 |
Renalytix AI plc
RNLX
|
2.29 M | - | 5.66 % | $ 22.7 M |  Britain |
 |
Chembio Diagnostics
CEMI
|
49.5 M | - | 0.22 % | $ 16.8 M | USA |
 |
Psychemedics Corporation
PMD
|
19.7 M | - | -1.84 % | $ 15.3 M | USA |
 |
T2 Biosystems
TTOO
|
7.19 M | - | -39.35 % | $ 313 K | USA |
 |
DermTech
DMTK
|
15.3 M | - | -11.32 % | $ 2.94 M | USA |
 |
Meridian Bioscience
VIVO
|
333 M | - | - | $ 1.49 B | USA |
 |
Akumin
AKU
|
750 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
11.7 M | - | -61.36 % | $ 2.46 M | USA |
 |
Quotient Limited
QTNT
|
38.5 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
Biocept
BIOC
|
25.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Invitae Corporation
NVTA
|
122 M | - | - | $ 21.2 M | USA |
 |
Brainsway Ltd.
BWAY
|
41 M | $ 12.23 | 1.35 % | $ 415 M | Israel |
 |
Trinity Biotech plc
TRIB
|
61.6 M | $ 5.77 | 1.41 % | $ 2.07 B |  Irlanda |
 |
Surmodics
SRDX
|
126 M | - | - | $ 608 M | USA |
 |
Heska Corporation
HSKA
|
257 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
6.37 M | - | -20.0 % | $ 1.06 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
73.7 M | - | - | $ 562 M | Britain |
 |
Fluidigm Corporation
FLDM
|
138 M | - | 1.08 % | $ 308 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
3.18 B | - | - | $ 10.7 B | USA |
|
Centogene N.V.
CNTG
|
128 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Global Cord Blood Corporation
CO
|
1.24 B | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
7.66 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
651 M | - | 0.12 % | $ 80.1 M | China |
 |
Aspira Women's Health
AWH
|
343 K | - | -6.19 % | $ 10.5 M | USA |
 |
Exact Sciences Corporation
EXAS
|
3.25 B | - | - | $ 19.8 B | USA |
 |
Interpace Biosciences
IDXG
|
38.7 M | $ 1.45 | 2.11 % | $ 6.41 M | USA |
 |
OpGen
OPGN
|
30.2 M | - | -16.95 % | $ 1.54 M | USA |
 |
PerkinElmer
PKI
|
2.86 B | - | -0.91 % | $ 14.7 B | USA |
 |
Soleno Therapeutics
SLNO
|
190 M | - | - | $ 2.69 B | USA |
 |
Enzo Biochem
ENZ
|
31.9 M | - | -8.98 % | $ 14.8 K | USA |
 |
Agilent Technologies
A
|
6.95 B | $ 171.29 | 2.09 % | $ 48.6 B | USA |
 |
Anixa Biosciences
ANIX
|
210 K | $ 2.95 | 6.5 % | $ 95.7 K | USA |
|
Biodesix
BDSX
|
88.5 M | $ 29.06 | 4.83 % | $ 219 M | USA |
 |
Biomerica
BMRA
|
4.45 M | $ 2.05 | 0.84 % | $ 5.98 M | USA |
 |
BioNano Genomics
BNGO
|
28.5 M | $ 1.45 | 0.96 % | $ 7.9 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
540 M | $ 15.83 | 0.62 % | $ 166 M | China |
 |
Bioventus
BVS
|
568 M | $ 13.52 | 2.97 % | $ 901 M | USA |
 |
CareDx, Inc
CDNA
|
380 M | $ 69.85 | 4.02 % | $ 3.72 B | USA |
 |
Co-Diagnostics
CODX
|
622 K | $ 1.1 | 1.85 % | $ 1.46 M | USA |
 |
Charles River Laboratories International
CRL
|
4.02 B | $ 310.77 | 7.07 % | $ 15.4 B | USA |
 |
Castle Biosciences
CSTL
|
344 M | $ 36.65 | 3.07 % | $ 1.06 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
11 B | $ 232.22 | 0.07 % | $ 25.8 B | USA |
 |
Danaher Corporation
DHR
|
24.6 B | $ 221.21 | 3.34 % | $ 158 B | USA |
 |
DarioHealth Corp.
DRIO
|
22.4 M | $ 5.8 | 1.24 % | $ 23.1 M | Israel |
 |
DexCom
DXCM
|
4.66 B | $ 86.9 | 1.8 % | $ 33.9 B | USA |